Literature DB >> 10763886

HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket.

C Pastori1, C Barassi, S Piconi, R Longhi, M L Villa, A G Siccardi, M Clerici, L Lopalco.   

Abstract

Human immunodeficiency virus (HIV)-specific IgA can be detected in cervical secretions, saliva, and sera of HIV-infected and HIV-uninfected individuals with a known exposure to the virus. IgA from HIV-uninfected exposed seronegative individuals (ESN) neutralize in vitro primary strains of HIV-1. We analyzed the epitopes of HIV recognized by serum HIV-specific IgA of ESN individuals to identify the antigenic correlates of HIV neutralization in exposed-uninfected subjects, and to verify whether different epitopes would be recognized by HIV-specific IgA of ESN and of HIV-infected patients. Results confirmed that HIV-neutralizing IgA are detected in sera of ESN and showed that neutralization of primary HIV strains is mediated by the recognition of different epitopes in HIV-infected patients and ESN. Thus, whereas IgA of HIV+ individuals recognize epitopes expressed both within gp120 and gp41, IgA of ESN exclusively bind to gp41-expressed epitopes. Epitope mapping revealed that the epitope recognized by serum IgA of ESN on gp41 is restricted to aa 581-584 (LQAR) and corresponds to coiled coil pocket in the alpha helic region. In contrast, the epitope seen by IgA of HIV-infected patients on gp41 is identified by two regions; the first is contained within the cystein loop (aa 589-618), the second correspond to C terminal region in the extra membrane region of gp 41 (aa 642-673). Thus, we have identified and characterized the epitopes that mediate neutralization of HIV in individuals in whom infection does not occur despite multiple exposures to the virus. These results have important implications for the development of a new therapy against HIV infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10763886

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  21 in total

1.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

2.  Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system.

Authors:  Franck Lemiale; Wing-pui Kong; Levent M Akyürek; Xu Ling; Yue Huang; Bimal K Chakrabarti; Michael Eckhaus; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.

Authors:  Curtis P Bradney; Gregory D Sempowski; Hua-Xin Liao; Barton F Haynes; Herman F Staats
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

5.  HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Authors:  Jennifer M Lund; Kristina Broliden; Maria N Pyra; Katherine K Thomas; Deborah Donnell; Elizabeth Irungu; Timothy R Muwonge; Nelly Mugo; Madhuri Manohar; Marianne Jansson; Romel Mackelprang; Mark A Marzinke; Jared M Baeten; Jairam R Lingappa
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

Review 6.  Neutralizing antibodies mechanism of neutralization and protective activity against HIV-1.

Authors:  Yi Xiao; Xiaonan Dong; Ying-Hua Chen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients.

Authors:  R Burrer; D Salmon-Ceron; S Richert; G Pancino; G Spiridon; S Haessig; V Roques; F Barre-Sinoussi; A M Aubertin; C Moog
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.

Authors:  Rosemary Stevens; Kristina E Howard; Sushila Nordone; MaryJo Burkhard; Gregg A Dean
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A.

Authors:  Alison Wright; Michael E Lamm; Yung T Huang
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

10.  Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals.

Authors:  Qin Lizeng; Charlotta Nilsson; Samer Sourial; Sören Andersson; Olav Larsen; Peter Aaby; Mariethe Ehnlund; Ewa Björling
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.